Introduction {#Sec1}
============

Coronavirus disease 2019 (COVID-19) which emerged in Wuhan, China, has spread to almost all countries and regions of the world, becoming one of the most lethal pandemic after the Spanish flu in 1918--1920. It is caused by an RNA virus (2019 novel coronavirus or 2019-nCoV or SARS-CoV-2). As of July 13, 2020, a total of 12,768,307 confirmed COVID-19 cases and 566,654 related deaths have been reported \[[@CR1]\]. Beyond its important morbidity and mortality and the huge burden of health care systems, COVID-19 has a massive societal and economic impact globally.

To date, there is no established curative treatment for COVID-19. Although some drugs such as hydroxychloroquine are integrated in treatment guidelines or under investigation in interventional studies, the management of COVID-19 is mostly supportive. \[[@CR2]--[@CR4]\] Identifying biological abnormalities induced by COVID-19 may contribute to a better understanding of the pathophysiology of the disease and ultimately guide the development of targeted adjuvant therapies besides antivirals drugs. Furthermore, such information on the biological profile of COVID-19 can guide clinicians in the assessment and treatment of these patients.

Clinically, most of COVID-19 cases (80%) are either asymptomatic or have mild forms. \[[@CR4], [@CR5]\] However, about 13.8 and 6.1% have severe and critical life-threatening disease that require admission to hospital and sometimes in the intensive care unit. \[[@CR5]\] In the context of outstretched heath care systems and limited resources, risk stratification is pivotal to identify patients who the most need in-hospital and intensive management. Biomarkers along with some clinical factors might help to predict adverse outcomes among COVID-19 patients. Hence, we conducted this systematic review and meta-analysis to summarize available data on the association between some common hematological, inflammatory, biochemical parameters and the severity of COVID-19.

Methods {#Sec2}
=======

This review is reported according to the MOOSE (Meta-analysis Of Observational Studies in Epidemiology) guidelines \[[@CR6]\].

Search strategy and selection criteria {#Sec3}
--------------------------------------

We searched PubMed, EMBASE and Web of sciences from inception to April 18, 2020, to identify studies in English or French reporting biological work-up results in patients with biologically confirmed (with polymerase chain reaction assays) COVID-19. The search strategies are presented in the appendix (Supplementary Table [1](#MOESM1){ref-type="media"} and [2](#MOESM1){ref-type="media"}). Furthermore, the reference list of eligible studies was analysed to identify potential additional data sources. For duplicates publications or studies conducted on the same group of patients, the study with the largest sample size was considered. We excluded studies from which we could not obtain data on the prevalence of abnormalities or the mean and standard deviation (or median and interquartile range) of the reported biomarker in severe and non-severe patients.

Data extraction and management {#Sec4}
------------------------------

Two investigators (CD and FTE) independently assessed the articles retrieved from the literature search to determine their potential eligibility based on titles and abstracts. The full texts of selected articles were then downloaded and assessed for final inclusion. Discrepancies were resolved by discussion and consensus.

An electronic data abstraction form was used by four investigators (CD, FTE, JRN and DLAW) to extracted relevant information in accordance with the objectives of the review. One investigator (JJN) crosscheck extracted data. For each study data extracted included: surname of the first author, year of publication, country and city where the study was conducted, study design, timing of data collection, sample size, proportion of males, study sample size, biological abnormalities reported, mean and standard deviation (or median and interquartile range) of reported biomarkers.

All patients presenting blood oxygen saturation ≤ 93%; respiratory failure; septic shock; multiple organ dysfunction; dyspnea;respiratory rate greater than 30/min, PaO2/FiO2 ratio \< 300, and/or lung infiltrates \> 50% of the lung field within 24--48 h were considered as severe cases as recommended by the World Health Organization. \[[@CR5]\]

Data synthesis and analysis {#Sec5}
---------------------------

A DerSimonian and Laird random-effects meta-analysis model was used to obtain the pooled effect size within the statistical software R (version 3.6.2). For studies reporting median and interquartile range of the biomarker, only those with a reported number of cases greater than 25 were included in the standardized mean difference (SMD) meta-analysis. Prior to pooling effect sizes, the standard deviation of each mean value was computed from the interquartile range by taking the difference between Q3 and Q1 and dividing by 1.35 as recommended in the Cochrane handbook of systematic review \[[@CR7]\]. Pooled OR and SMD of each biomarker are reported with their 95% confidence intervals.

Cochran's χ^2^ and the I^2^ tests were used respectively to assess the presence and the amount of heterogeneity, with the cut-off of I^2^ values of 25, 50 and 75% representing low, medium and high heterogeneity respectively \[[@CR8], [@CR9]\]. Publication bias was assess by the inspection of the Funnel plot and the Egger test (*p* \< 0.10) \[[@CR10]\]. Unless otherwise specify, a *p* value \< 0.05 was considered as statistically significant for all analysis.

Results {#Sec6}
=======

Characteristics of included studies {#Sec7}
-----------------------------------

The bibliographical search yielded 287 eligible articles, of which 31 were finally retained for the systematic review, and 16 for the meta-analysis as depicted in the study selection process (Supplementary Figure [1](#MOESM1){ref-type="media"}). Two studies were conducted in Singapore \[[@CR11], [@CR12]\] and all the others in China in 2020 \[[@CR13]--[@CR41]\] (Table [1](#Tab1){ref-type="table"}). Twelve of the included studies were conducted in Wuhan. Twenty-eight studies had collected data retrospectively while three were prospective. All included studies except one (which was cross sectional) were case series with patients having a mean age ranging from 9 to 70.5 years in severe cases and from 7.5 to 59.7 years in non-severe cases. The proportion of males ranged from between 40.7 and 73%. Three studies reported data on survivors and non-survivors (Table [1](#Tab1){ref-type="table"}). Table 1Characteristics of included studiesCaiQiCase serieChinaShenzhenSingle centerHospitalRetrospectiveNon-servere Vs Servere41785NR233NRNRNR**Cai**QCase serieChinaShenzhenSingle centerReferal hospitalRetrospectiveNon-servere Vs Servere2985862.524041Liver diseases:13.9%; Type II diabetes:13.8%; Hypertension:37.9%;Cardiac diseases:22.4%;Liver diseases:8.3%; Type II diabetes:4.2; Hypertension:10.4;Cardiac diseases:5.0%**Chen**XCase serieChinaChongqingSingle centerHospitalRetrospectiveNon-servere Vs Servere7815NR63NRNRNR**Chen**GCase serieChinaWuhanSingle centerHospitalRetrospectiveModerate Vs Severe2111611052Hypertension: 36.4%; diabetes: 18.2%Hypertension: 10%; diabetes:10%**Fan**BCase serieSingaporeUnclearSingle centerHospitalProspectiveICU VS No-ICU679545841NRNR**Feng**YCase serieChinaWuhanMulticenterHospitalRetrospectiveModerate Vs Critical476706135251Hypertension: 35.7%; diabetes 8.6%; cardiovascular diseases: 17.1%; malignancy: 8.6%;COPD: 15.7%;immunosuppression: 7.1%;Hypertension: 20.7%;diabetes 9.1%; cardiovascular diseases 6%; malignancy: 1.4%;COPD: 2.3%;immunosuppression: 0.6%;**Guan**WCase serieChinaUnclearMulticenterUnclearRetrospectiveAdmission to an intensive care unit (ICU), use of mechanical ventilation, or death10991735292645Hepatitis B: 2.4%; Diabetes:16.2%;Hypertention: 23.7%;COPD:3.5%; CHD: 5.8%; Cerebro-Vas diseases: 2.3%;Immunodeficiency:0%;Cancer: 1.7%Hepatitis B: 0.6%; Diabetes: 5.7%;Hypertention:13.4%;COPD: 0.6%; CHD: 1.8%; Cerebro-Vas diseases:1.2%;Immunodeficiency:0.2%;Cancer:0.8%**Han**HCross sectionalChinaWuhanSingle centerHospitalProspectiveOrdinary Vs Severe9435NR49NRNRNR**Huang**CCase serieChinaWuhanSingle centerHospitalProspectiveNon-servere Vs Servere4113492849Diabetes:8%;Hypertention: 15%;COPD:8%; CVD: 23%;Immunodeficiency:%;Cancer: 0%Diabetes: 25%;Hypertention: 14%;COPD:0%;CVD: 11%;Cancer: 4%**Li**YCase serieChinaHuazhongSingle centerDepartment of Thoracic SurgeryRetrospectiveNon-servere Vs Servere259NR16NRHypertention: 11.1%;COPD:44.4%;diabetes:11.1%;CHD: 11.1Hypertention:6.3%;COPD:6.3%;diabetes: 0%;CHD:18.8**Li**KCase serieChinaUnclearSingle centerHospitalRetrospectiveNon-servere Vs Servere832553.75841Hypertention:8%;COPD: 16.0%;diabetes:28.0%;CHD: 4.0%Hypertention5.2%;COPD: 1.7%;diabetes:0.0%;CHD:0.0%**Liu**YCase serieChinaShenzhenSingle centerHospitalRetrospectiveMechanical ventilation VS No Mechanical ventilation12664.5652Hypertention:17.6%;COPD:%;diabetes:16.7%;CHD:33.3%;cancer:0%;chronic liver diseases:0%; chronic renal diseases:16.7%**Liu**WCase serieChinaWuhanMulticenterHospitalRetrospectiveCommon Vs Severe788NR70NRHypertention:10.3%;COPD: 5.1%;diabetes:6.4%;cancer:5.1%**Mao**LCase serieChinaWuhanMulticenterNeurologyRetrospectiveNon-servere Vs Servere2148858.212648.9Hypertention:36.4%; diabetes: 17.0%; cardiac/cerebral disease: 8.0%;Cancer: 5.7%; chronic kidney disease:2.3%Hypertention: 15.1%; diabetes:11.9%; cardiac/cerebral disease:6.3%;Cancer:6.3%; chronic kidney disease:3.2%**Qian**GCase serieChinaZhejiangMulticenterHospitalRetrospectiveNon-servere Vs Servere919668249NRNR**Qin**CCase serieChinaTongjiSingle centerHospitalRetrospectiveNon-servere Vs Servere4522866116653Hypertention:36.7%;COPD: 3.1%;diabetes:18.5%;cancer:3.5%;CVD:8.4;CeVD:2.8%; chronic liver diseases: 1%;Tuberculosis:2.4%; chronic kidney diseases: 2.1%Hypertention:18.1%;COPD: 1.8%;diabetes:13.3%;cancer:2.4%;CVD:1.8%;CeVD:1.8%; chronic liver diseases:1.8%;Tuberculosis:1.2%; chronic kidney diseases: 2.4%**Qiu**HCase serieChinaZhejiangMulticenterPaediatricRetrospectiveMild Vs Moderate36199177.5NRNR**Qu**RCase serieChinaHuizhouSingle centerHospitalRetrospectiveNon-servere Vs Servere303602749.4NRNR**Ruan**QCase serieChinaJin,TongjiMulticenterHospitalRetrospectiveDeath Vs Discharge15068NR82NRNRNR**Wan**SCase serieChinaChongqingSingle centerHospitalRetrospectiveNon-servere Vs Servere13540569544Hypertention:10%;COPD:10%;diabetes:22.5%;cancer: 7.5%;CVD:15%;chronic liver diseases:2.5%; pulmonary diseases:2.5%Hypertention:9.4%;COPD:0%;diabetes: 3.1%;cancer:1.5%;CVD:1%; chronic liver diseases: 1%;Tuberculosis: %;diseases:0%**Wang**ZCase serieChinaWuhanMulticenterHospitalRetrospectiveNon-servere Vs Servere691470.55537Hypertention:36%;COPD: 14%;diabetes:43%;cancer: 7%;CVD:36%;chronic liver diseases:0%;Hypertention: 7%;COPD: 4%;diabetes: 2%;cancer: 5%;CVD:5%;chronic liver diseases:2%**Wang**RCase serieChinaFuyangSingle centerHospitalRetrospectiveNon-servere Vs Servere1252549.410039.7Comorbidities: 48%Comorbidities:22%**Wang**DCase serieChinaWuhanSingle centerHospitalRetrospectiveNon-servere Vs Servere138366610251Hypertention:58.3%;COPD: 8.3%;diabetes:22.2%;cancer:11.1%;CVD:25.0%;chronic liver diseases:0%; CeVD:16.7%;HIV:0%Hypertention:21.6%;COPD:1.0%;diabetes:5.9%;cancer: 5.9%;CVD:10.8%;chronic liver diseases:3.9%; CeVD:1.0%;HIV:2.0%**Wu**CCase serieChinaWuhanSingle centerHospitalRetrospectiveSurvivor Vs Non-survivor2014468.54050^a^Hypertention:36.4%; diabetes:25.0%; CVD:9.1%^a^Hypertention:17.5%; diabetes:12.5%;CVD:2.5%**Xu**YCase serieChinaUnclearSingle centerRadiologyRetrospectiveMild/Moderate/Severe/critical503NR9NRNRNR**Yang**XCase serieChinaWuhanSingle centerHospitalRetrospectiveSurvivor Vs Non-survivor523264.62059.7^a^COPD:6%;diabetes:22%;cancer:3%;CVD:9%;chronic liver diseases:0%; CeVD:22%^a^COPD:10%;diabetes:10%;cancer:5%;CVD:10%;chronic liver diseases:0%;CeVD:0%**Young**BCase serieSingaporeNRMulticenterHospitalRetrospectiveRequire Vs not require supp Oxygen186561237Comorbidities:67%Comorbidities:8%**Yun**LCase serieChinaShanghaiSingle centerHospitalRetrospectiveNo-servere Vs Servere2922165.527148.7NRNR**Zhang**JCase serieChinaWuhanMulticenterHospitalRetrospectiveNon-servere Vs Servere14058648251.5Hypertention:37.9%; COPD:3.4%; diabetes:13.8%;CHD:6.9%;liver diseases:6.9%; CeVD: 3.4%Hypertention:24.4%; COPD:0%; diabetes:11.0%;CHD:3.7%;liver diseases:5.0%; CeVD: 1.2%**Zheng**FCase serieChinaChangshaSingle centerHospitalRetrospectiveNon-servere Vs Servere161305713140Hypertention:40%; COPD:6.7%; diabetes:6.7%; CHD:6.7%;chronic liver diseases:3.1%; CeVD:3.3%Hypertention:7.6%; COPD:3.1%; diabetes:3.8%;CHD:1.5%;chronic liver diseases:0%;CeVD:2.3%**Zhou**FCase serieChinaWuhanMulticenterPulmonary hospitalRetrospectiveSurvivor Vs Non-survivor191546913752^a^ Hypertention:48%; COPD:7%; diabetes: 31%; cancer:0%; CHD:14%;chronic kidney diseases:4%^a^ Hypertention: 23%; COPD:1%; diabetes: 14%; cancer:1%; CHD:1%;chronic kidney diseases:1%^a^Survivor Vs Non-survivors; *CeVD* Cerebrovascular diseases; *CVD* Cardiovascular diseases; *COPD* chronic obstructive pulmonary diseases; *CHD* coronary heart diseases; *NR* Not reported

Full blood count abnormalities {#Sec8}
------------------------------

Severe COVID-19 cases had significantly lower lymphocyte count (SMD = -0.57, 95%CI:-0.71; − 0.42; *P-value:* \< 0.001; *n* = 3337), proportion of lymphocytes (SMD = -0.81, 95%CI: − 1.12; − 0.49; *P-value:*\< 0.001;*n* = 1974), thrombocytes (SMD = -0.26, 95%CI: − 0.48; − 0.04; *P-value:*0.02;*n* = 2064), eosinophils (SMD = − 0.28, 95%CI:-0.50; − 0.06; *P-value:*0.01; *n* = 436) and haemoglobin (SMD = -0.20, 95%CI: − 0.37,-0.03; *P-value:*0.02;*n* = 843). They had a significantly higher neutrophil count (SMD = 0.52, 95%CI: 0.28;0.76; *P-value:*\< 0.001; *n* = 2156) (Table [2](#Tab2){ref-type="table"}). Moreover, non-survivor cases of COVID-19 had a significantly lower level of lymphocytes (SMD = -0.67, 95% CI: − 1.18; − 0.17; *P-value:* 0.009; *n* = 327) and higher level of white blood cells (SMD = 0.89, 95%CI:0.04; 1.75; *P-value:* 0.04; *n* = 275) (Table [3](#Tab3){ref-type="table"}). Table 2Summary results of the meta-analysis of mean values of each Biomarker in severe vs non-severe casesAnomaliesSMD (95% CI)P-valueHeterogeneity\
I2 (%)Number of studiesSample size for severeSample size for Non-severeInflammation Procalcitonin0.72 (0.34;1,11)\< 0.0018764671042 CRP1.34 (0.83;1.86)\< 0.0019596701304 IL-60.93 (0.25;1.61)0.007933369506 ESR0.27 (−0.16;0.70)0.229044351029Blood routine Lymphocytes count-0.57 (−0.71; −0.42)\< 0.00161128882449 Lymphocytes %-0.81 (−1.12; − 0.49)\< 0.001623367306 Thrombocytes-0.26 (− 0.48; − 0.04)0.027274451619 Eosinophils−0.28 (− 0.50; − 0.06)0.0102114322 Neutrophils0.52 (0.28;0.76)\< 0.0018096461510 Haemoglobin−0.20 (− 0.37; − 0.03)0.0204165678 Monocytes−0.09(− 0.27;0.08)0.30144372426 White Blood Cells0.13 (−0.14;0.39)0.35901111332566 CD3+ T−0.77(−0.95; − 0.59)\< 0.00102307437Cardiac injury biomarkers CK-MB0.68(0.48;0.87)\< 0.001304185965 Troponin I0.71(0.42;1.00)\< 0.0010257373Biochemestry CK0.48(0.10;0.87)0.018973431317 Myoglobin1.14(0.81;1.47)\< 0.001663149863 ALAT0.53(0.34;0,71)\< 0.00168105071785 ASAT0.96(0.58;1.34)\< 0.0019194531650 Albumin−1.67(−2.40; −0.94)\< 0.001934185855 Creatinemia0.18(0.01;0.35)0.044983681417 Blood urea nitrogen0.58(0.23;0.93)0.001835277920 Total bilirubin0.32(0.18;0.47)\< 0.0012873441253 LDH1.36(0.75;1.98)\< 0.0019573431317 Potassium−0.10(−0.43;0.23)0.557932481061 Sodium−0.19(− 0.72;0.34)0.49913231983 γ-GT1.03(0.83;1.22)\< 0.00102143473Blood clothing PT0.48(0.23;0.73)\< 0.001163111246 D-dimer0.54(0.31;0.77)\< 0.0016973481235 aPT0.17(−0.23;0.57)0.40744164274 Fibrinogen0.09(−0.56;0.74)0.7877256320*SMD* Standardized mean difference; *CRP* C-reactive protein; *CK* Creatine kinase; *IL-6* interleukin-6; *ALAT* alanine amino-transferase;*ASAT* aspartate amino-transferase; *LDH* Lactate dehydrogenese; *PT* prothrombin time; *aPT* activated partial thromboplastin;Table 3Summary results of the meta-analysis of mean values of each Biomarker in non-survivor and survivor casesAnomaliesSMD (95% CI)P-valueHeterogeneity\
I2 (%)Number of studiesSample size for Non-survivorSample size survivorInflammation IL-61.23(0.77;1.68)\< 0.00161298177Blood routine Lymphocytes count−0.67(−1.18; −0.17)0.009753130197 White Blood Cells0.89(0.04; 1.75)0.0490298177Biochemestry Creatinemia−0.09(−0.46;0.27)0.621227660 Total bilirubin0.55(0.20;0.89)0.002027660 LDH1.48(0.57;2.40)0.00290298170 Ferritin0.76(−0.33;1.90)0.1893290122Blood clothing PT0.30(−0.14;0.75)0.18683130188*SMD* Standardized mean difference; *IL-6* interleukin-6; *LDH* Lactate dehydrogenese; *PT* prothrombin time; *CD3+ T* CD3+ positif T lymphocytes

Furthermore, cases of severe COVID-19 were more likely to present lymphopenia (RR =1.66, 95%CI: 1.26;2.20; *P-value:*0.002; *n* = 1636), and thrombocytopenia (RR =1.86, 95%CI: 1.59;2.17; *P-value:* \< 0.001; *n* = 1226) but not leukopenia (RR =0.93,95%CI: 0.46;1.86; *P-value:* 0.81; *n* = 1684) (Table [4](#Tab4){ref-type="table"}). More details on the meta-analysis and forest plots are available in the appendix ([Supplementary file](#MOESM1){ref-type="media"}). Table 4Summary results of the meta-analysis of odd ratio of each Biomarker in severe vs non-severe casesAnomaliesRR (95% CI)P-valueHeterogeneity\
I2 (%)Number of studiesSample size for severeSample size for non-severeInflammation Eleveted procalcitonin2.94 (2.09; 4.15)\< 0.001329321941 Eleveted CRP1.41 (1.17; 1.70)0.003083281021Blood routine Lymphopenia1.66(1.26;2.20)0.00230114111225 Leucopenia0.93(0.46;1.86)0.8183103841300 Thrombocytopenia1.86(1.59;2.17)\< 0.00105250976 Thrombocytosis0.88(0.26;2.95)0253122Biochemestry Eleveted LDH2.03(1.42;2.90)0.003577239899 Eleveted ASAT2.27(1.76;2.94)\< 0.0012683541184 Eleveted ALAT160(1.34;1.90)0.0026052831042 Eleveted CK2.61(1.35;5.05)0.01376248841 Eleveted Creatininemia3.66(1.53; 8.81)0.0204227857 Eleveted total bilirubin1.42(0.18;11.26)0.2802158725Blood clothing D-dimer1.50(0.89; 2.56)0.0803156510*OR* odd ratio; *CRP* C-reactive protein; *CK* Creatine kinase; *IL-6* interleukin-6; *ALAT* alanine amino-transferase;*ASAT* aspartate amino-transferase; *LDH* Lactate dehydrogenese

Blood clotting abnormalities {#Sec9}
----------------------------

There was a significant difference in D-dimer and prothrombin time (PT) between severe and non-severe cases, with severe cases having a higher D-dimer level (SMD = 0.54,95%CI:0.31;0.77; *P-value:* \< 0.001; *n* = 1583) and prothrombin time (SMD = 0.48, 95%CI:0.23;0.73; *P-value:* \< 0.001; *n* = 357).

Increased cardiac injury biomarkers in severe cases {#Sec10}
---------------------------------------------------

Troponin I blood level were significantly higher in severe patients (SMD = 0.71, 95%CI: 0.42;1.00; *P-value:*\< 0.001; *n* = 430) as well as CK-MB levels (SMD = 0.68,95%CI: 0.48;0.87; *P-value:*\< 0.001; *n* = 1150), and this was consistent across all studies included in the meta-analysis of the above-mentioned biomarkers (Table [2](#Tab2){ref-type="table"}).

Inflammation {#Sec11}
------------

Severe COVID-19 cases had significantly higher blood level of procalcitonin (SMD = 0.72, 95%CI: 0.34;1,11; *P-value:* \< 0.001; *n* = 1509), interleukin-6 (SMD = 0.93, 95%CI: 0.25;1.61; *P-value:* 0.007; *n* = 875),and C-reactive protein (SMD = 1.34, 95%CI:0.83;1.86; *P-value:* \< 0.001; *n* = 1974) (Table [2](#Tab2){ref-type="table"}). Moreover, IL-6 was significantly higher in non-survivor compare to survivor cases (SMD = 1.23, 95%CI: 0.77;1.68; *P-value:*\< 0.001; *n* = 275).

Severe cases were more likely to have a higher procalcitonin level (RR =2.94, 95%CI: 2.09; 4.15; *P-value:* \< 0.001; *n* = 1262), and CRP (RR =1.41,95%CI: 1.17; 1.70; *P-value:* 0.003; *n* = 1349) (Table [4](#Tab4){ref-type="table"}).

Biochemical abnormalities {#Sec12}
-------------------------

Overall, severe COVID-19 cases were found to have higher level of ALAT (SMD = 0.53, 95%CI: 0.34;0,71; *P-value:* \< 0.001; *n* = 2292) and ASAT (SMD = 0.96, 95%CI: 0.58;1.34; *P-value:* \< 0.001; *n* = 2103), LDH (SMD = 1.36, 95%CI: 0.75;1.98; *P-value:* \< 0.001; *n* = 1660), CK (SMD = 0.48, 95%CI: 0.10;0.87; *P-value:0.01*; n = 1660), total bilirubin (SMD = 0.32, 95%CI: 0.18;0.47; *P-value:* \< 0.001; *n* = 1597), γ-GT (SMD = 1.03, 95%CI: 0.83;1.22;*P-value:*\< 0.001; *n* = 616), myoglobin (SMD = 1.14, 95%CI: 0.81;1.47; *P-value:* \< 0.001; *n* = 1012) and blood urea nitrogen (SMD = 0.32, 95%CI: 0.18;0.47; *P-value:*0.001; *n* = 1197) and Creatininemia (SMD = 0.18, 95%CI: 0.01;0.35; *P-value:* 0.04; *n* = 1785). Albuminemia was found to be lower in severe cases (SMD-1.67,95%CI -2.40; − 0.94; *P-value:\< 0.001*; *n* = 1040) (Table [2](#Tab2){ref-type="table"}).

Severe COVID-19 cases were more likely to have higher blood level of ASAT(RR = 2.27, 95%CI: 1.76;2.94; *P-value:*\< 0.001; *n* = 1538), CK(RR = 2.61, 95%CI: 1.35;5.05; *P-value:* 0.01; *n* = 1086), Creatininemia (RR =3.66, 95%CI: 1.53; 8.81; *P-value:* 0.02; *n* = 1084), LDH (RR =2.03, 95%CI: 1.42;2.90; *P-value:* 0.003; *n* = 1138) (Table [4](#Tab4){ref-type="table"}).

Concerning non-survivors, total bilirubin (SMD = 0.55,95%CI: 0.20;0.89; *P-value:* 0.002; *n* = 136) and LDH (SMD = 1.48,95%CI: 0.57;2.40; *P-value:* 0.002; *n* = 268) were significantly higher in non-survivors compare to survivors (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec13}
==========

This review shows that patients with a severe form of COVID-19 have higher level of CK-MB,troponin I, D-dimer, prothrombin time, procalcitonin, interleukin-6, C-reactive protein, ALAT, ASAT, LDH, CK, total bilirubin, γ-GT, myoglobin, blood urea nitrogen, creatininemia and lower level of lymphocyte, thrombocytes, eosinophils, haemoglobin and albuminemia.

Inflammation and COVID-19 {#Sec14}
-------------------------

It has been shown that COVID-19 infection is associated with a severe systemic immune response drive by a "cytokine storm". \[[@CR42]--[@CR44]\] Our data point to an association between procalcitonin (PCT), CRP levels and the severity of the disease. This is supported by previous findings which has reported elevated levels of several pro inflammatory cytokines including IL-2, IL-6, IL-7, MCP1, and TNF alpha, which contributes to increase classical inflammatory biomarkers such as PCT and CRP and are found to be higher in the severe forms of the disease. \[[@CR42], [@CR43], [@CR45]\] Mechanistically, it has been show that, after the virus entry in the pneumocytes via the ACE2 receptor, it triggers a systemic inflammatory response, creating an immune dysfunction with a hyperactivity of T lymphocytes and the release of pro inflammatory cytokines mentioned above. \[[@CR42], [@CR43], [@CR46]\] If the inflammation is initially protective, it appears secondarily that most cellular and tissue lesions are more the result of hyperinflammation than of the direct effect of the virus. \[[@CR42], [@CR43]\] These two phenomena may favor at the respiratory level, pulmonary lesions, by hypercapillary permeability and pulmonary edema, leading to acute respiratory distress. \[[@CR42], [@CR47]\] Hyperinflammation at the systemic level may lead to vascular, thrombotic and cytokines' toxicity phenomena, resulting in multisystemic lesions. \[[@CR43], [@CR44], [@CR48]\] Moore et al. showed that, these severe, multi-organ damage may worsen the prognosis despite supportive therapies. \[[@CR49]\] Thus for clinicians, the measurement of classical and accessible inflammatory markers namely PCT and CRP, may help assessing the hyper inflammatory activity, and thus the severity of cases of severe infections. Furthermore, the use of therapies targeting inflammation to reduce the deleterious effects of the cytokine storm appear to be necessary. In this line, some studies have reported the beneficial effects of immunosuppressive and immunomodulatory therapies. \[[@CR50]--[@CR52]\] However, the benefit of the use of corticosteroids and non-steroidal anti-inflammatory drugs to reduce hyperinflammation during the 2019-nCoV infection is still controversial. \[[@CR39]--[@CR41]\]

Cardiac biomarkers imbalanced and COVID-19 {#Sec15}
------------------------------------------

Our analysis revealed that severe COVID-19 cases have elevated levels of biomarkers of cardiomyocytes injury such as Troponin I, CK-MB, CK and myoglobin. Numerous previous researches have reported a cardiac involvement in patients with 2019-nCoV. \[[@CR53]--[@CR56]\] In a recently published study, Lippi and colleagues reported that the values of cardiac Troponin I were significantly increased in COVID-19 cases with severe disease than in those without. \[[@CR55]\] Notwithstanding the incomplete knowledge on its pathophysiology, the mainly suggested mechanisms are: myocardial ischemia due to increased oxygen demand but in the context of hypoxemia and plaque disruption triggered by cytokine storm; these two being most frequently encountered among patients with coronary artery disease. \[[@CR57]--[@CR60]\] Also, myocardial inflammation, which can be the result of systemic immune response is another mechanism of heart injury among COVID-19 cases. \[[@CR61], [@CR62]\] Likewise, it has been hypothesised a direct viral toxicity through the interaction with ACE2 receptors highly expressed by some pericytes. \[[@CR59]\] A thorough cardiac assessment should therefore be conducted in the follow-up of severe COVID-19 cases and manage properly to avoid adverse outcome.

Lymphopenia and other full blood count imbalance in severe COVID-19 cases {#Sec16}
-------------------------------------------------------------------------

Hematological changes encountered in the course of the novel coronavirus infection are common and concern mainly white blood cells and platelets. \[[@CR63]\] In our study, some keys parameters modifications, notably lymphopenia and thrombocytopenia, are associated with severe form of the disease. \[[@CR64]\]

Indeed, we found decreased overall mean levels of lymphocyte count among severe 2019-nCoV patients. Moreover, patients with severe 2019-nCoV infection were more likely to have lymphopenia. Low lymphocyte count has also been reported for other viral respiratory infection such as the one due to Respiratory Syncytial Virus (RSV). \[[@CR65]\] This immune response marked by a profound lymphopenia seem to be is delay complication that come after an early massive release of cytokine during the course of the SRAS-Cov-2 lung injury. \[[@CR66]--[@CR68]\] The effects of COVID-19 on lymphocytes can be explained by direct and/or indirect mechanisms. The direct insult could be related to 2019-nCoV cytotoxicity, sustained by active viral replication within pool of infected lymphocytes. \[[@CR67], [@CR69]\] However, angiotensin-converting enzyme 2 (ACE2) has been identified as a functional cellular receptor for the COVID-19, a protein that is not expressed on circulating B or T lymphocytes. \[[@CR66], [@CR70]\] Studies suggested a potential role of alveolar macrophages which can promote viral entry via antigen presentation to T lymphocytes. \[[@CR66], [@CR67]\] Indirect lymphocytes damage could appear through huge cytokines release which can induce cells apoptosis. \[[@CR66], [@CR68], [@CR69]\] In addition, high glucocorticoids levels induced by severe 2019-nCov can pertain to the down regulation of proinflammatory lymphokine ultimately lead to the lymphocyte activation and proliferation alteration . \[[@CR67], [@CR68]\]. \[[@CR71]\] Clinicians should therefore keep in mind that severe cases of COVID-19 have depressed lymphocyte levels and are therefore more prone to infection.

Another key hematological disturbance found in our review was thrombocytopenia. Indeed, our analysis revealed significantly reduced mean platelets count in cases with severe COVID-19. Moreover, patients with severe form of the disease were more likely to have low platelets counts. Some potential mechanisms of SRAS-associated thrombocytopenia have been proposed. Coronavirus can infect bone marrow cells and thereby reduce platelet production. \[[@CR72]\] Indeed some strains of coronavirus like HCoV-229 have their receptor on humans cells like those of kidney, lung and platelets, named Human amino peptidase N (CD13). \[[@CR73]\] 2019-nCoV infection may also increase peripheral destruction of platelet \[[@CR72], [@CR74]\] by immunological mechanism by generating auto antibodies and immune complex. \[[@CR75]\] Similar response have been reported for other viruses like HIV 1 in which Anti-platelet membrane GPIIIa49--66 IgG antibodies can cross-react with the HIV-1GP 160/120 antigen. \[[@CR75]\] Other pathways can be the consumption of platelet following severe lung inflammation result in platelets activation and formation of microthrombi. \[[@CR72]\] Thrombocytopenia, which makes cases with severe forms of the disease susceptible to primary coagulation impairment, is therefore an important element to consider and address in the daily management and evaluation of these patients.

COVID-19 and blood coagulation {#Sec17}
------------------------------

Four main coagulation biomarkers disturbances were found in severe COVID-19 cases namely higher serum D-dimers, longer prothrombin time (PT), and lower platelets counts. Moreover, we found that patients with severe 2019-nCoV infection are more likely to have increase serum D-dimers.

Coronavirus disease 2019 can affect haemostasis and blood coagulation in many ways, both regarding abnormal bleeding risk and thromboembolism. \[[@CR72], [@CR76]--[@CR79]\] In addition to thrombocytopenia mechanistic hypotheses stated earlier, it must be suggest the potential implication of COVID-19 liver injury an aetiological element of haemostasis disorder though the impaired production of coagulation factors. \[[@CR72], [@CR76], [@CR77]\]

Concerning D-dimers, increased levels might be the result of the sepsis-induced disseminated intravascular coagulation and reflect thromboembolic risk in severe COVID-19 cases. \[[@CR80]--[@CR82]\] There are mounting evidences supporting the key pathological role of thromboembolic processes in SARS-CoV-2 disease and severity. \[[@CR83]--[@CR86]\] Due to the low specificity of this biomarker, its results in Covid-19 patients should be interpreted in the context of other associated conditions that may also potentially increase D-dimer levels.

Decreased platelet counts and increased prothrombin time in patients with covid-19 are probably due to consumption coagulopathy. The latter occurs as a result of an abnormal increase in the activation of procoagulant pathways which induces a decrease in plasma concentrations of fibrinogen, platelets and other clotting factors. \[[@CR87]\] A daily assessment of the coagulation profile of cases with severe forms of the disease appears vital and the correction of those abnormalities unavoidable to improve the prognosis. Cases of COVID-19 with blood-clotting abnormalities should be managed very closely and invasive treatments that may lead to bleeding should be avoided.

Biochemical abnormalities in severe COVID-19 cases {#Sec18}
--------------------------------------------------

Numerous liver biomarkers abnormalities have been described as being associated with COVID-19 encompassing increased levels of total bilirubin, transaminases, γ-GT, LDH, and low albumin levels. \[[@CR88]--[@CR91]\] Our results revealed that some of these biomarkers (ASAT/ALAT, γ-GT, LDH) have a significantly higher level in severe cases, and that severe cases are more likely to have high levels of ASAT and LDH.

It has been reported a virus-induced cytopathic effect notably through the binding with the ACE2 receptor for its target cells entry. \[[@CR91], [@CR92]\] Another potential triggering factor of detrimental liver consequences is immune-mediated inflammation in parallel with the "cytokine storm". \[[@CR76], [@CR93], [@CR94]\] Moreover, the immune responses ensured by B and T cells lymphocytes can also sustain this inflammation. \[[@CR67], [@CR68]\] It has also been put forward stress on sepsis related ischemic/hypoxic liver injury as putative mechanisms of abnormal hepatic function. \[[@CR95], [@CR96]\] Hepatic sinuses congestion related to thrombosis and/or high levels of positive end expiratory pressure can also be a contributing explanatory mechanisms of liver damage. \[[@CR93], [@CR95], [@CR97]\] Likewise, COVID-19 patients may experience drug-induced liver injury (DILI), \[[@CR93], [@CR98]\] and reactivation of pre-existing hepatic conditions (going from viral hepatitis to liver cirrhosis). \[[@CR90], [@CR97], [@CR99]\] Therefore, drugs which are known to be hepatotoxic or which are metabolized by the liver should be administered with caution or should be avoided in severe cases. Nevertheless, the results of liver biomarkers in COVID-19 cases must be interpreted in the context of the presence of other comorbidities that may induce an increase in these biomarkers.

Our findings point to an overall higher levels of urea nitrogen and creatinine among COVID-19 severe cases. Further studies are needed to better understand renal involvement in severe COVID-19 cases, especially since some pathophysiological hypotheses suggest the possibility of kidney damages related to COVID-19 infection. \[[@CR100]--[@CR103]\]

The current research provides evidence-based elements that can help clinicians in decision making when dealing with COVID-19 cases. Future studies should explore novel biomarkers, such as non-coding RNAs or proteomics, for disease progression and severity of COVID-19 and similar diseases in order to build powerful prediction tools.

The results of the current review should be interpreted in the context of some limitations. Firstly, it was not possible to assess the dynamic of biomarkers and to determine whether the samples were taken on admission or later during hospitalization. Therefore, the kinetic of biomarkers during the disease progression to severity cannot be established. Secondly, all the studies included in the meta-analysis were from China. Different biological patterns might be observed across populations from various geographical and ethnic background. Therefore, this limits the generalizability of our findings and call to more research on the topic in population from different countries and ethnicities. Thirdly, the measurement of biomarkers was probably different between studies, with various devices and diagnostic reference values. However, in most studies, there was low to moderate heterogeneity, suggesting that observations were consistent across studies. Nevertheless, this study is one of the first to analyse potential biomarkers associated with the severity of 2019-nCoV infection. We used state-of-the-art statistical methods in order to derive the most accurate estimates.

Conclusion {#Sec19}
==========

Some inflammatory (procalcitonin, CRP), haematologic (lymphocyte, Thrombocytes), and biochemical (CK-MB, Troponin I, D-dimer, ASAT, ALAT, LDH, γ-GT) biomarkers are significantly associated with severe COVID-19. These biomarkers might help in prognostic risk stratification of patients with COVID-19. Our findings could also contribute in the establishment of an accurate and reproducible COVID-19 biological severity score.
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